ELP1 and brain neoplasm: These results are significant, since they demonstrate that it is feasible to increase brain tumor uptake of thermally responsive ELP drug carriers with focused hyperthermia, but also thermal targeting of the Bac-ELP1-H1 polypeptide to the tumors resulted in significant delayed onset of neurological deficits, 80% tumor volume reduction, and at least doubled survival.